In European children between 2 to 5 years of age, Prevenar should cover about 62% to 83% of the clinical isolates responsible for invasive pneumococcal disease.
Euroopa 2 - kuni 5- aastastel lastel katab Prevenar umbes 62% kuni 83% invasiivset pneumokokk- haigust põhjustavatest kliinilistest isolaatidest.